Dr. Lu Weining is an associate professor at Boston University. He has been working on rare genetic diseases for the past 20 years. His translational research program has adopted combined human and mouse molecular genetics approaches to identify a number of genetic disease genes for the study of kidney and urinary tract development and pathogenesis of rare kidney diseases. Dr. Lu was named Boston University’s Innovator of the Year in 2019, an award bestowed annually on a faculty member who “translates his or her world-class research into inventions and innovations that benefit humankind,” for his research that led to the development of a potential new drug for rare kidney diseases.
Dr. Jin Xiaowei is currently the Head of Business Development of Hua Medicine. Previously she was Vice President of Discovery Biology at Medicilon Shanghai. She has over 20 years of extensive experience in global biopharmaceutical industry, ranging from early discovery to clinical development and business strategy. Dr. Jin started her industry career in drug discovery as a research scientist at Biogen. She received her PhD in Biochemistry and Pharmacology from the University of Virginia and completed her postdoctoral training at Harvard Medical School. She also earned her BS from the University of Science & Technology of China with highest honors. She has been one of the key organizers and chairpersons for the annual China Rare Disease Summit, the largest and most influential event dedicated to rare disease in China.